Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 65

1.

Role of PD-1 in regulating T-cell immunity.

Jin HT, Ahmed R, Okazaki T.

Curr Top Microbiol Immunol. 2011;350:17-37. doi: 10.1007/82_2010_116. Review.

PMID:
21061197
2.

A peptide inhibitor of FOXP3 impairs regulatory T cell activity and improves vaccine efficacy in mice.

Casares N, Rudilla F, Arribillaga L, Llopiz D, Riezu-Boj JI, Lozano T, López-Sagaseta J, Guembe L, Sarobe P, Prieto J, Borrás-Cuesta F, Lasarte JJ.

J Immunol. 2010 Nov 1;185(9):5150-9. doi: 10.4049/jimmunol.1001114. Epub 2010 Sep 24.

3.

Immunologic response to xenogeneic gp100 DNA in melanoma patients: comparison of particle-mediated epidermal delivery with intramuscular injection.

Ginsberg BA, Gallardo HF, Rasalan TS, Adamow M, Mu Z, Tandon S, Bewkes BB, Roman RA, Chapman PB, Schwartz GK, Carvajal RD, Panageas KS, Terzulli SL, Houghton AN, Yuan JD, Wolchok JD.

Clin Cancer Res. 2010 Aug 1;16(15):4057-65. doi: 10.1158/1078-0432.CCR-10-1093. Epub 2010 Jul 20.

4.

Dependence of T cell antigen recognition on T cell receptor-peptide MHC confinement time.

Aleksic M, Dushek O, Zhang H, Shenderov E, Chen JL, Cerundolo V, Coombs D, van der Merwe PA.

Immunity. 2010 Feb 26;32(2):163-74. doi: 10.1016/j.immuni.2009.11.013. Epub 2010 Feb 4.

5.

Peptide vaccines prevent tumor growth by activating T cells that respond to native tumor antigens.

Jordan KR, McMahan RH, Kemmler CB, Kappler JW, Slansky JE.

Proc Natl Acad Sci U S A. 2010 Mar 9;107(10):4652-7. doi: 10.1073/pnas.0914879107. Epub 2010 Jan 26. Erratum in: Proc Natl Acad Sci U S A. 2010 Mar 9;107(10):4788-9.

6.

Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine.

Dangoor A, Lorigan P, Keilholz U, Schadendorf D, Harris A, Ottensmeier C, Smyth J, Hoffmann K, Anderson R, Cripps M, Schneider J, Hawkins R.

Cancer Immunol Immunother. 2010 Jun;59(6):863-73. doi: 10.1007/s00262-009-0811-7. Epub 2009 Dec 31.

PMID:
20043222
7.

Fine structural variations of alphabetaTCRs selected by vaccination with natural versus altered self-antigen in melanoma patients.

Wieckowski S, Baumgaertner P, Corthesy P, Voelter V, Romero P, Speiser DE, Rufer N.

J Immunol. 2009 Oct 15;183(8):5397-406. doi: 10.4049/jimmunol.0901460. Epub 2009 Sep 28.

8.

Serum carcinoembryonic antigen level in non-small-cell lung cancer patients with preoperative normal serum level.

Tomita M, Shimizu T, Hara M, Ayabe T, Onitsuka T.

Gen Thorac Cardiovasc Surg. 2009 Jun;57(6):303-6. doi: 10.1007/s11748-008-0397-6. Epub 2009 Jun 17.

PMID:
19533276
9.

Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells.

Grosso JF, Goldberg MV, Getnet D, Bruno TC, Yen HR, Pyle KJ, Hipkiss E, Vignali DA, Pardoll DM, Drake CG.

J Immunol. 2009 Jun 1;182(11):6659-69. doi: 10.4049/jimmunol.0804211.

10.

The molecular signature of CD8+ T cells undergoing deletional tolerance.

Parish IA, Rao S, Smyth GK, Juelich T, Denyer GS, Davey GM, Strasser A, Heath WR.

Blood. 2009 May 7;113(19):4575-85. doi: 10.1182/blood-2008-10-185223. Epub 2009 Feb 9.

11.

The antigen-specific CD8+ T cell repertoire in unimmunized mice includes memory phenotype cells bearing markers of homeostatic expansion.

Haluszczak C, Akue AD, Hamilton SE, Johnson LD, Pujanauski L, Teodorovic L, Jameson SC, Kedl RM.

J Exp Med. 2009 Feb 16;206(2):435-48. doi: 10.1084/jem.20081829. Epub 2009 Feb 2.

12.

Endogenous naive CD8+ T cell precursor frequency regulates primary and memory responses to infection.

Obar JJ, Khanna KM, Lefrançois L.

Immunity. 2008 Jun;28(6):859-69. doi: 10.1016/j.immuni.2008.04.010. Epub 2008 May 22.

13.

T cell receptor specificity for major histocompatibility complex proteins.

Marrack P, Rubtsova K, Scott-Browne J, Kappler JW.

Curr Opin Immunol. 2008 Apr;20(2):203-7. doi: 10.1016/j.coi.2008.03.008. Epub 2008 May 2. Review.

14.

Age-dependent tolerance to an endogenous tumor-associated antigen.

McWilliams JA, Sullivan RT, Jordan KR, McMahan RH, Kemmler CB, McDuffie M, Slansky JE.

Vaccine. 2008 Mar 28;26(15):1863-73. doi: 10.1016/j.vaccine.2008.01.052. Epub 2008 Feb 20.

15.

Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen.

Speiser DE, Baumgaertner P, Voelter V, Devevre E, Barbey C, Rufer N, Romero P.

Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3849-54. doi: 10.1073/pnas.0800080105. Epub 2008 Mar 4. Erratum in: Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10632.

16.

Level of HER-2/neu protein expression in breast cancer may affect the development of endogenous HER-2/neu-specific immunity.

Goodell V, Waisman J, Salazar LG, de la Rosa C, Link J, Coveler AL, Childs JS, Fintak PA, Higgins DM, Disis ML.

Mol Cancer Ther. 2008 Mar;7(3):449-54. doi: 10.1158/1535-7163.MCT-07-0386. Epub 2008 Mar 4.

17.
18.

Baculovirus-infected insect cells expressing peptide-MHC complexes elicit protective antitumor immunity.

Jordan KR, McMahan RH, Oh JZ, Pipeling MR, Pardoll DM, Kedl RM, Kappler JW, Slansky JE.

J Immunol. 2008 Jan 1;180(1):188-97.

19.

Naive CD4(+) T cell frequency varies for different epitopes and predicts repertoire diversity and response magnitude.

Moon JJ, Chu HH, Pepper M, McSorley SJ, Jameson SC, Kedl RM, Jenkins MK.

Immunity. 2007 Aug;27(2):203-13. Epub 2007 Aug 16.

20.

Mobilizing the low-avidity T cell repertoire to kill tumors.

McMahan RH, Slansky JE.

Semin Cancer Biol. 2007 Aug;17(4):317-29. Epub 2007 Jun 23. Review.

Supplemental Content

Support Center